The US Meals and Drug Administration (FDA) has permitted the subcutaneous administration of vedolizumab (Entyvio) for upkeep remedy in adults with reasonably to severely energetic Crohn’s illness (CD) after induction remedy with intravenous (IV) vedolizumab.
The transfer follows the FDA’s approval final 12 months of subcutaneous vedolizumab for upkeep therapy of adults with reasonably to severely energetic ulcerative colitis (UC).
The humanized immunoglobulin G1 monoclonal antibody is offered as a single-dose prefilled pen (Entyvio Pen).
The FDA first permitted the IV formulation of the biologic in 2014 for sufferers with reasonable to extreme UC and CD who can not tolerate different therapies or in whom such therapies have failed.
The approval of subcutaneous vedolizumab for upkeep therapy of CD is predicated on the part 3, randomized, double-blind, placebo-controlled VISIBLE 2 trial.
The trial enrolled 409 grownup sufferers with reasonably to severely energetic CD who had scientific response at week 6 following two doses of open-label IV vedolizumab at weeks 0 and a pair of.
At week 6, they had been randomly allotted in a 2:1 ratio to obtain vedolizumab 108 mg administered by subcutaneous injection or placebo each 2 weeks. The first endpoint was scientific remission at week 52, which was outlined as a complete Crohn’s Illness Exercise Index rating ≤ 150.
The outcomes confirmed that considerably extra sufferers receiving subcutaneous vedolizumab than placebo achieved long-term scientific remission (48% vs 34%; P < .01), the corporate stated in a information launch.
The security profile of subcutaneous vedolizumab is usually in keeping with the identified security profile of IV vedolizumab, with the addition of injection-site reactions (together with injection-site erythema, rash, pruritus, swelling, bruising, hematoma, ache, urticaria, and edema).
“Crohn’s illness is a posh and normally progressive illness for which an acceptable administration plan is crucial. My major aim as a clinician is at all times to get sufferers to realize remission,” Timothy Ritter, MD, senior medical director, GI Alliance Analysis, and assistant professor of medication, Burnett College of Medication at TCU, Fort Value, Texas, stated within the information launch.
“In VISIBLE 2, about half of sufferers handled with Entyvio SC achieved long-term scientific remission. The information from VISIBLE 2 reaffirm the well-established efficacy profile of Entyvio, no matter route of administration,” Ritter added.
